Document:

<PAGE>   1
                                                                   Exhibit 10(s)

                                                             [Commitment Letter]

                            BANKERS TRUST CORPORATION
                                       and
                        FIRST CHICAGO CAPITAL CORPORATION
                          c/o Bankers Trust Corporation
                               130 Liberty Street
                            New York, New York 10006

                                                                  March 15, 2000

LENNAR CORPORATION
700 N.W. 107th Avenue
Miami, Florida 33172

                         Re: U.S. Home Merger Financing

Ladies and Gentlemen:

            We understand that you intend to consummate a merger (the "Merger")
between Len Acquisition Corporation, one of your wholly-owned subsidiaries
("Newco"), and U.S. Home Corporation, a Delaware corporation ("USH"), in which
Newco will be the surviving entity, and to conduct a tender offer and consent
solicitation (the "Tender Offer') for certain public indebtedness of USH.

            We further understand that the funding requirements for the Merger
and Tender Offer will be approximately $1.4 billion and such amount, together
with ongoing working capital needs, will be provided solely from (i) a senior
secured revolving credit and term loan facility of up to $1.3 billion (the "Bank
Financing") to be drawn in part on the closing date of the Merger (the "Closing
Date"), (ii) approximately $265.8 million of your common stock (based on the
closing sale price of $15.81 on February 11, 2000) and (iii) the issuance and
sale of Debt Securities (as defined below). The Merger, the Tender Offer, the
Bank Financing, the issuance of your common stock as described above, the bridge
loan contemplated by this letter, and the issuance and sale of the Debt
Securities are herein collectively referred to as the "Transaction".

            In connection with the Transaction, you have engaged Deutsche Bank
Securities Inc. and Banc One Capital Markets, Inc. as joint book-running
managers (the "Joint Book-Running Managers") to sell or place senior debt
securities issued by you (the "Debt Securities").

            You have requested that Bankers Trust Corporation and First Chicago
Capital Corporation (the "Co-Lenders") commit to provide you funds in the amount
of up to $500 million in the form of a senior unsecured bridge loan and/or term
loan to be made available as described in Section 1 hereof (the "Bridge Loan").
You shall have the right to designate additional financial institutions
reasonably acceptable to the Co-Lenders to provide a portion of the Bridge Loan;
provided that in no event will any other financial institution provide a larger
portion of the Bridge Loan than the respective individual portions to be
provided by each Co-Lender (any such additional lenders and the Co-Lenders being
collectively referred to as the "Lenders").

            Accordingly, subject to the terms and conditions set forth or
incorporated in this letter, the Lenders agree with you as follows:

<PAGE>   2

Lennar Corporation
March 15, 2000
Page 2.

            Section 1. Bridge Loan. The Lenders hereby commit, subject to the
terms and conditions hereof and in the Summary Term Sheet attached hereto as
Exhibit A (the "Term Sheet"), to provide to you a senior unsecured bridge loan
and/or term loan in the aggregate principal amount of up to $500 million on the
Closing Date, each such Lender to be obligated to provide the portion of the
Bridge Loan set forth below its signature on the signature pages hereto. The
proceeds of the Bridge Loan shall be used solely to pay the applicable purchase
price (including any premium or consent fee and including any accrued interest
or discount) (the "Purchase Price") of outstanding debt securities of USH that
are tendered for purchase or redemption ("Tendered Debt") in accordance with the
terms of the Tender Offer and/or other costs of the Merger. The principal terms
of the Bridge Loan are summarized in the Term Sheet.

            Unless the commitment of the Lenders hereunder shall have been
terminated pursuant to Section 7, the Lenders shall have the exclusive right to
provide the Bridge Loan or other bridge or interim financing required in
connection with the Transaction.

            You hereby represent and covenant that based on your review and
analysis, to the best of your knowledge, (a) all information other than
Projections (as defined below) which has been or is hereafter made available to
the Lenders by you or your representatives, advisors or affiliates in connection
with the transactions contemplated hereby (the "Information") is, or in the case
of Information made available after the date hereof will be, correct in all
material respects and does not and will not contain any untrue statement of a
material fact or omit to state a material fact known to you and necessary to
make the statements contained therein, in the light of the circumstances under
which such statements were or are made, not misleading and (b) all financial
projections concerning the Transaction that have been or are hereafter made
available to the Lenders by you or your representatives, advisors or affiliates
in connection with the transactions contemplated hereby (the "Projections") have
been or, in the case of Projections made available after the date hereof, will
be prepared in good faith based upon reasonable assumptions (it being understood
that the Projections are subject to significant uncertainties and contingencies,
many of which are beyond your control and that no assurance can be given that
such Projections will be realized). You agree to supplement the Information and
the Projections from time to time until the earlier of (i) consummation of the
Transaction and (ii) termination of the commitments hereunder so that the
representation and warranty made in the preceding sentence is correct as of such
date. In arranging and syndicating the Bridge Loan, the Lenders will be using
and relying on the information and the Projections. The representations and
covenants contained in this paragraph shall remain effective until a definitive
financing agreement is executed and thereafter the disclosure representations
contained herein shall be terminated and of no further force and effect.

            Section 2. Financing Documentation. The making of the Bridge Loan
will be governed by definitive loan and related agreements and documentation
(collectively, the "Financing Documentation") in form and substance reasonably
satisfactory to the Lenders and to you. The Financing Documentation shall be
prepared by Willkie Farr & Gallagher, special counsel to the Lenders. The
Financing Documentation shall contain such covenants, terms and conditions as
are consistent with this letter and the Term Sheet and such other covenants,
terms, conditions, representations, warranties, events of default and remedies
provisions as shall be satisfactory to the Lenders and you.

            Section 3. Conditions. The obligation of the Lenders under Section 1
of this letter to provide the Bridge Loan is subject to fulfillment of the
following conditions:

<PAGE>   3

Lennar Corporation
March 15, 2000
Page 3.

            (a) Merger Agreement. You, Newco and USH have entered into a Plan
      and Agreement of Merger, dated as of February 16, 2000 (the "Merger
      Agreement"), on terms and in form and substance reasonably satisfactory to
      the Lenders. The Merger Agreement shall not have been amended in any
      material respect without the consent of the Lenders, which consent shall
      not be unreasonably withheld. All conditions precedent to the Merger
      contained in the Merger Agreement shall have been performed or complied
      with substantially on the terms set forth therein and not waived without
      the consent of the Lenders, which consent shall not be unreasonably
      withheld, and the Merger shall have been consummated.

            (b) Tender Offer. You shall have made the Tender Offer on terms and
      in form and substance reasonably satisfactory to the Co-Lenders, including
      the elimination of restrictive covenants, and shall have used your best
      efforts to solicit and accept for purchase on the Closing Date all of the
      following USH debt issues (the "Target Issues"): 7.95% Senior Notes due
      2001, 8.25% Senior Notes due 2004, 7.75% Senior Notes due 2005, 8.88%
      Senior Subordinated Notes due 2007, and 8.875% Senior Subordinated Notes
      due 2009. In addition, to the extent you shall not have accepted for
      purchase 100% of each of the Target Issues, you shall have made
      arrangements in form and substance satisfactory to the Co-Lenders (i) to
      reduce permanently the Bank Financing, applying such reductions first
      against the 364-day revolving credit portion and second against the
      long-term revolving credit portion of the Bank Financing (any such
      reduction to become effective 91 days after the Closing Date and to be
      itself reduced by the aggregate principal amount of the Target Issues that
      is retired pursuant to any "change of control" put; however, such amounts
      will be temporarily unavailable under the Bank Financing until the 91 days
      have passed and the "change of control" put has been funded or the Bank
      Financing has been permanently reduced), (ii) to implement a "covenant
      defeasance" in accordance with the terms of the indentures for the Target
      Issues in accordance with the terms thereof, or (iii) to effect any
      combination of (i) or (ii) above. To the extent Debt Securities are not
      issued, the Bridge Loan will be funded in full on the Closing Date.

            (c) Financing Documentation. You and the Lenders shall have entered
      into the Financing Documentation relating to the Bridge Loan and the
      transactions contemplated thereby on terms and in form and substance
      reasonably satisfactory to you and the Lenders.

            (d) Bank Financing. You shall have entered into definitive
      documentation on terms and in form and substance reasonably satisfactory
      to the Lenders with respect to the Bank Financing (collectively with all
      documents and instruments related thereto or delivered in connection
      therewith, the "Bank Documents") with a commercial lender or lenders or a
      syndicate of commercial lenders. The Bank Documents shall be in full force
      and effect, the parties thereto shall be in compliance with all material
      agreements thereunder and proceeds of the initial drawing shall be
      available.

            (e) No Adverse Change or Development, Etc. (i) Nothing shall have
      occurred since November 30, 1999 (and the Lenders shall have become aware
      of no facts or conditions not previously known to the Lenders) which the
      Lenders shall reasonably determine could have a material adverse effect on
      the rights or remedies of the Lenders, or on your ability to perform your
      obligations to the Lenders or which could have a materially adverse effect
      on your business, property, assets, nature of assets, liabilities,
      condition (financial or otherwise), results of operations or prospects
      after giving effect to the Transaction; (ii) nothing shall have occurred

<PAGE>   4

Lennar Corporation
March 15, 2000
Page 4.

      since September 30, 1999 (and the Lenders shall have become aware of no
      facts or conditions not previously known to the Lenders) which the Lenders
      shall reasonably determine, individually or in the aggregate, could have a
      material adverse effect on the business, operations, results of
      operations, properties, assets, liabilities or condition (financial or
      otherwise) of USH; (iii) trading in securities generally on the New York
      or American Stock Exchange shall not have been suspended; minimum or
      maximum prices shall not have been established on any such exchange; (iv)
      a banking moratorium shall not have been declared by New York or United
      States authorities; and (v) there shall not have been (A) an outbreak or
      escalation of hostilities between the United States and any foreign power,
      or (B) an outbreak or escalation of any other insurrection or armed
      conflict involving the United States or any other national or
      international calamity or emergency, or (C) any material change in the
      general financial markets of the United States which, in each case, in the
      reasonable judgment of the Lender would materially and adversely affect
      the ability to sell or place the Debt Securities.

            (f) Capital Structure. Your pro forma consolidated capital structure
      and Newco's pro forma consolidated capital structure, in both cases after
      giving effect to the Transaction, shall be consistent with the capital
      structure contemplated herein, and other than the Bridge Loan and the Bank
      Financing neither you, Newco, USH nor any subsidiary, after giving effect
      to, and upon consummation of, the Transaction, shall have incurred
      indebtedness for money borrowed after the date hereof (other than pursuant
      to revolving credit facilities existing on the date hereof and approved by
      the Lenders). The $80 million secured revolving credit facility of USH's
      subsidiary, U.S. Home Mortgage Corporation, that terminates September 30,
      2001 shall remain available in such amount and any "change of control" or
      other default or termination right resulting from the Merger shall have
      been waived or eliminated or such facility shall have been replaced with a
      revolving credit facility of at least the same size on terms and with
      lenders satisfactory to the Lenders.

            (g) Opinions. As of the Closing Date, the Lenders shall have
      received a legal opinion from your counsel, and covering matters,
      reasonably acceptable to the Lender.

            (h) Due Diligence. The Lenders shall have completed their legal,
      tax, accounting and environmental analysis and review and shall be
      satisfied in their sole discretion with the results thereof. It is
      understood and agreed that, following such completion, the Lenders shall
      remove the condition contained in this paragraph or shall promptly notify
      you of any non-satisfaction on their part with the due diligence
      referenced above.

            (i) Take-Out Bank. You shall have engaged the Joint Book-Running
      Managers (the "Take-Out Bank") to publicly offer or privately place the
      Debt Securities or equity or equity-linked securities, the proceeds of
      which will be used to repay in whole or in part the Bridge Loan ("Take-Out
      Securities"). You shall have prepared a registration statement or
      prospectus supplement relating to the issuance of the Take-Out Securities
      and the Take-Out Bank shall have been afforded the opportunity to market
      and shall have marketed such Take-Out Securities pursuant to a prospectus
      or prospectus supplement for such a period as is customary to complete the
      sale of such securities. You, Newco and USH shall have used your
      reasonable best efforts to assist the Take-Out Bank in marketing the
      Take-Out Securities, including, without limitation, having prepared the
      prospectus or prospectus supplement relating thereto, having made your
      senior management and the senior management of USH and other
      representatives of you and

<PAGE>   5

Lennar Corporation
March 15, 2000
Page 5.

      USH available (at mutually agreeable times) to participate in meetings
      with prospective investors and having provided such information and
      assistance as the Take-Out Bank shall have reasonably requested during the
      course of such marketing process.

            Section 4. Securities Demand. The Financing Documentation will
provide that upon request (a "Request") from the Take-Out Bank made at any time
after the three month anniversary of the Closing Date and prior to the
Conversion Date (as defined in the Term Sheet), you shall take all reasonable
actions necessary or desirable, to the extent within your power, so that the
Take-Out Bank can, as soon as practicable after such Request, publicly offer or
privately place Debt Securities (the "Initial Request Date"). The Financing
Documentation will also provide that upon notice by the Take-Our Bank (a
"Take-Out Securities Notice"), at any time and from time to time following the
Initial Request Date, you will issue and sell Debt Securities upon such terms
and conditions as specified in the Take-Out Securities Notice; provided,
however, that for either a Request or a Take-Out Securities Notice (i) fixed
interest rates shall be determined by the Take-Out Bank in light of the then
prevailing market conditions, but in no event shall the interest rate on the
Debt Securities exceed 14% per annum; (ii) the maturity of any Debt Securities
shall not be earlier than 12 months after the scheduled maturity of the term
facility provided as part of the Bank Financing (as in effect on the Closing
Date); (iii) the Debt Securities will contain such terms, conditions and
covenants (including limitations as to optional redemption) as are customary for
similar high yield financings and as are satisfactory in all respects to you and
the Take-Out Bank; and (iv) all other arrangements with respect to the Debt
Securities shall be reasonably satisfactory in all respects to you and the
Take-Out Bank in light of the then prevailing market conditions. The foregoing
shall not limit your ability to refinance the Bridge Loan by other means.

            In addition, you covenant and agree subsequent to the funding date
of any portion of the Bridge Loan to use your reasonable best efforts to assist
the Take-Out Bank in marketing the Debt Securities to refinance the Bridge Loan,
including, without limitation, preparing a prospectus supplement or an offering
memorandum relating thereto, making your senior management and the senior
management of USH and other representatives of you and USH available (at
mutually agreeable times) to participate in meetings with prospective investors
and providing such information and assistance as the Take-Out Bank shall
reasonably request during the course of such marketing process.

            Section 5. Indemnification and Contribution. You agree to indemnify
the each Lender and each of its affiliates and each person in control of each
Lender and each of its affiliates and the respective officers, directors,
employees, agents and representatives of each Lender and its affiliates and
control persons, as provided in the Indemnity Letter dated the date hereof and
attached hereto (the "Indemnity Letter").

            Section 6. Expenses. In addition to any fees that may be payable to
the Lenders as provided in the Fee Letter dated the date hereof and attached
hereto (the "Fee Letter") and regardless of whether any of the transactions
contemplated by this letter are consummated, if this letter agreement is
terminated, the Bridge Loan is made available or the Financing Documentation is
executed and delivered, you hereby agree to reimburse the Lenders for all
reasonable fees and disbursements of legal counsel, including but not limited to
the reasonable fees and disbursements of Willkie Farr & Gallagher, the Lenders'
special counsel, and all of the Lenders' travel and other reasonable
out-of-pocket expenses incurred in connection with the Transaction or otherwise
arising out of the Lenders' commitment hereunder.

<PAGE>   6

Lennar Corporation
March 15, 2000
Page 6.

            Section 7. Termination. The commitment hereunder to provide the
Bridge Loan shall terminate, unless expressly agreed to by the Lenders in their
sole discretion to be extended to another date, on the earlier of (A) 5:00 p.m.,
New York time, on June 3, 2000, if no portion of the Bridge Loan has been funded
(other than as a result of failure of the Lenders to fulfill their obligations
hereunder), and (B) the termination of the Merger Agreement or the Tender Offer
in accordance with the terms thereof. No such termination of such commitment
shall affect your obligations under Sections 5 and 6 hereof, which shall survive
any such termination.

            Section 8. Assignment; Syndication. This letter shall not be
assignable by any party hereto without the prior written consent of the other
parties (other than, in the case of the Lenders, to an affiliate of the Lenders,
it being understood that any such affiliate shall be subject to the restrictions
set forth in this Section 8); provided, however, that the Lenders shall have the
right, in their sole discretion, to syndicate the Facility and their commitment
with respect thereto among banks or other financial institutions or qualified
institutional buyers (as defined in Rule 144A under the Securities Act of 1933)
pursuant to the Financing Documentation or otherwise and to sell, transfer or
assign all or any portion of, or interests or participations in, the Facility
and their commitment with respect thereto and any notes issued in connection
therewith; provided, further, that Bankers Trust Corporation shall be the
book-running syndication agent and any syndication shall reduce the Lenders'
respective commitment percentages on a pro rata basis. You agree to use your
reasonable best efforts, whether prior to or after the initial Funding Date of
any Bridge Loan, to assist the Lenders in syndicating the Facility or their
commitment with respect thereto, including, without limitation, in connection
with (x) the preparation of an information package regarding the Transaction,
including the Information and the Projections described in Section 1 hereof, and
(y) meetings and other communications with prospective Lenders, including making
your senior management and the senior management of USH and other
representatives of you and USH available (at mutually agreeable times) to
participate in such meetings.

            Section 9. Miscellaneous. THIS LETTER SHALL BE GOVERNED BY, AND
CONSTRUED IN ACCORDANCE WITH, THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD
TO THE PRINCIPLES GOVERNING CONFLICTS OF LAWS, AND ANY RIGHT TO TRIAL BY JURY
WITH RESPECT TO ANY CLAIM, ACTION, SUIT OR PROCEEDING ARISING OUT OF OR
CONTEMPLATED BY THIS LETTER IS HEREBY WAIVED. YOU HEREBY SUBMIT TO THE
NONEXCLUSIVE JURISDICTION OF THE FEDERAL AND NEW YORK STATE COURTS LOCATED IN
THE CITY OF NEW YORK IN CONNECTION WITH ANY DISPUTE RELATED TO THIS LETTER OR
ANY MATTERS CONTEMPLATED HEREBY. This letter (including the provisions of the
Fee Letter and the Indemnity Letter specifically incorporated herein) embodies
the entire agreement and understanding between you and the Lenders and
supersedes all prior agreements and understandings relating to the subject
matter hereof. This letter may be executed in any number of counterparts, each
of which shall be an original, but all of which shall constitute one instrument.

            The Lenders reserve the right to employ the services of their
affiliates (including the Joint Book-Running Managers) in providing services
contemplated by this letter and to allocate, in whole or in part, to their
affiliates certain fees payable to the Lenders in such manner as the Lenders and
its affiliates may agree in their sole discretion. You acknowledge that the
Lenders may share with any of its affiliates (including the Joint Book-Running
Managers) and such affiliates may share with the Lenders (in each case, subject
to any confidentiality agreements applicable thereto), any information

<PAGE>   7

Lennar Corporation
March 15, 2000
Page 7.

related to you or your affiliates, USH (including information relating to
creditworthiness) or the Transaction.

            This letter and the Term Sheet (collectively, the "Commitment
Letter") are furnished for your benefit, and may not be relied upon by any other
person or entity. You agree that the Commitment Letter is for your confidential
use only and that neither its existence nor the terms thereof will be disclosed
by you to any person other than your officers, directors, employees,
accountants, attorneys, lenders, lessors and other advisors, and then only on a
"need to know" basis in connection with the transactions contemplated hereby and
on a confidential basis. Notwithstanding the foregoing, following your
acceptance of the provisions hereof and your return of an executed counterpart
of the Commitment Letter to us as provided below, (i) you shall be permitted to
furnish a copy hereof to USH and its advisors in connection with the proposed
Merger, (ii) you may make public disclosure of the existence and amount of the
commitment under the Commitment Letter and the identity of the Lenders, (iii)
you may file a copy of the Commitment Letter in any public record in which it is
required by law to be filed and (iv) you may make such other public disclosure
of the terms and conditions hereof as, and to the extent, you are required by
law, in the opinion of your counsel, to make. Except as otherwise required by
law or unless the Lenders have otherwise consented, you are not authorized prior
to your acceptance of the Commitment Letter to show or circulate this letter to
any other person or entity (other than (x) your legal or financial advisors in
connection with your evaluation hereof and (y) to USH and its advisors in
connection with the proposed Merger).

<PAGE>   8

Lennar Corporation
March 15, 2000
Page 8.

            If you are in agreement with the foregoing, please sign and return
to the Lenders at 130 Liberty Street, New York, New York 10006 the enclosed copy
of this letter, the Indemnity Letter and the Fee Letter no later than 6:00 p.m.,
New York time, on March 17, 2000, whereupon the undertakings of the parties
shall become effective to the extent and in the manner provided hereby. This
offer shall terminate if not so accepted by you on or prior to that time.

                                           Very truly yours,

                                           BANKERS TRUST CORPORATION

                                           By: _____________________________
                                               Name:
                                               Title:
                                               Commitment Percentage: 50%

                                           FIRST CHICAGO CAPITAL CORPORATION

                                           By: _____________________________
                                               Name:
                                               Title:
                                               Commitment Percentage: 50%

Accepted and Agreed to as of
the date first above written:

LENNAR CORPORATION

By: ____________________________
    Name:
    Title:<PAGE>   1
                                                                   EXHIBIT 10(q)

     [Note: Certain portions of this document have been marked "[c.i.]" to
indicate that confidentiality has been requested for this confidential
information. The confidential portions have been omitted and filed separately
with the Securities and Exchange Commission.]

                                SUPPLY AGREEMENT

     This Agreement is entered into the 24th day of December, 1993 by and
between DUSA Pharmaceuticals, Inc. (hereinafter, "DUSA"), a corporation
organized and existing under the laws of the State of New Jersey whose principal
offices are located at 337 Roncesvalles Avenue, Toronto, Ontario Canada MGR 2M7,
and Sochinaz S.A. (hereinafter, "SOCHINAZ"), a corporation registered under the
laws of the Canton of Valais, Switzerland whose principal offices are located at
Rte du Simplon, CH-1895 Vionnaz Switzerland.

                              W I T N E S S E T H:

     WHEREAS, DUSA is developing a porphyrin precursor generally known as
5-aminolevulinic acid (hereinafter "ALA"), which is useful as an active
ingredient in diagnosis and therapy; and

     WHEREAS, SOCHINAZ is an experienced manufacturer of ALA; and

     WHEREAS, DUSA needs a reliable supply of ALA and wishes to purchase ALA
from SOCHINAZ and SOCHINAZ wishes to sell ALA to DUSA for that purpose;

     NOW THEREFORE, in consideration of the foregoing and the mutual covenants
contained herein, the parties agree as follows:

     1.   Definitions. As used herein, the term

     1.1  "ALA" shall mean 5-aminolevulinic acid.

     1.2  "Product" or "Products" shall mean ALA meeting the specifications set
forth on Exhibit A, attached hereto and incorporated by reference herein, as
such specifications may be amended from time to time by DUSA.

     1.3  "Territory" shall mean the world.

     2.   Purchase and Sale of Products; Resale Restrictions.

     2.1  Subject to the terms of this Agreement, DUSA agrees to purchase from
SOCHINAZ, and SOCHINAZ agrees to sell to DUSA, all of DUSA's requirements for
Products for sale in the Territory, during the term of this Agreement.

     2.2  SOCHINAZ agrees not to manufacture, deal in or sell ALA for
pharmaceutical use, in or to any other party who to SOCHINAZ knowledge intends
to sell or resell the same for ultimate resale in the Territory. SOCHINAZ may
sell ALA for other uses with the prior written consent of DUSA.

<PAGE>   2

     2.3  Notwithstanding Paragraph 2.2 above, DUSA shall have the right to
secure an alternate supplier for [c.i.]* of DUSA's requirements.

     2.4  Notwithstanding Paragraph 2.2 above, DUSA shall have the right to
purchase any or all of DUSA's requirements for Product from third parties in the
event SOCHINAZ is unable to supply in a timely manner all Products ordered in
three consecutive purchase orders, whether or not such orders are in excess of
DUSA's forecasts.

     2.5  Notwithstanding Paragraph 2.2 above, DUSA shall have the right to
purchase Product from third parties to the extent such other Product is (i) of
comparable quality; (ii) covered by a drug master file as required by the
relevant health regulatory authorities; and (iii) available in equivalent
quantities from third parties at prices which are [c.i.] lower than prices
available from SOCHINAZ hereunder, unless SOCHINAZ shall offer to meet such
lower price. If DUSA duly exercises this right, DUSA shall purchase from
SOCHINAZ a quantity equivalent to [c.i.] of the latest annual rolling forecast
referred to in Paragraph 3.2 below.

     2.6  Products shall be supplied in units and packaging specified by DUSA.

     3.   Supply of Products.

     3.1  All sales by SOCHINAZ to DUSA under this Agreement shall be governed
exclusively by the terms of this Agreement. No additional or different terms set
forth in any of either parties purchase order, acknowledgment or other forms or
correspondence shall be of any force or effect.

     3.2  DUSA shall provide to SOCHINAZ, on or before [c.i.] during the term of
this Agreement, a rolling forecast of the volume of its requirements for
Products during the following [c.i.]. Such forecast shall be deemed a planning
target and not constitute an order for the Products and shall not be binding on
DUSA. DUSA shall only be bound to purchase such quantities of Product as
referred to in Paragraph 3.3 below. SOCHINAZ shall inform DUSA within [c.i.] of
SOCHINAZ' receipt of any of DUSA'S rolling forecast should SOCHINAZ be unable to
ship the quantities set forth in DUSA'S estimates by the date and time
indicated.

     3.3  DUSA will place firm orders with SOCHINAZ for its requirements for the
Products, giving (unless otherwise agreed) [c.i.] notice prior to the requested
date of delivery. All orders shall be promptly acknowledged by SOCHINAZ. Insofar
as these orders are not in excess of the latest forecast for the period during
which the Products are to be delivered then SOCHINAZ shall supply the Products
in accordance with DUSA's orders and meet the specific month requested by DUSA
for delivery. Orders being

                                       2
<PAGE>   3

[c.i.] in excess of DUSA's forecast for the period during which the Products are
to be delivered have to be confirmed in writing by SOCHINAZ indicating the
delivery date within the next sixty (60) days.

     3.4  Each batch of the Products supplied to DUSA by SOCHINAZ will comply
with the specifications for the Products as set out in Exhibit A to this
Agreement. SOCHINAZ will supply to DUSA along with each batch of the Products a
Certificate of Analysis stating the active ingredient percentages, the
analytical control method and specifications therefor, the shelf life of the
Product, and certifying that the particular batch complies with the
specification for the Products.

     3.5  Any dispute as to the analysis of any batch of the Products will be
settled by the decision of a mutually acceptable independent analytical
laboratory.

     3.6  SOCHINAZ will retain samples of raw materials as well as samples of
Products of each manufactured batch for a minimum period of the shelf life of
the Products plus one year, both during and after the term of this Agreement.

     3.7  DUSA and any regulatory authorities of the Territory shall be entitled
to inspect at normal office hours and upon prior notice the premises of SOCHINAZ
where the Products are manufactured and where the quality control is executed
and to inspect the process of manufacture.

     3.8  No alterations of any specification for the Products or the
manufacturing process of the Products can be made without the approval of DUSA.

     3.9  At DUSA's option, DUSA may order, and SOCHINAZ shall deliver, on a
consignment basis, up to three (3) months' supply of Product. Such supply shall
not be deemed to be part of SOCHINAZ's inventory for purposes of calculating the
amount to be purchased by DUSA under Paragraph 2.5 above.

     4.   Terms of Payment for Products.

     4.1  The prices at which SOCHINAZ agrees to sell the Products shall be as
set out in Exhibit B, and incorporated herein by reference, until the end of the
term of this Agreement. Such prices shall be at DUSA's option F.O.B. DUSA's
offices in Toronto, Ontario, Canada, Denville, New Jersey, or other place
designated by DUSA in the United States of America. The 1980 U.N. Convention of
Contracts for the International Sales of Goods shall not be applicable.

     4.2  Title and risk of loss to Product sold hereunder shall pass at DUSA's
option when delivered to DUSA in its offices in

                                       3
<PAGE>   4

Toronto, Ontario, Canada, or in the United States of America. Customs fees,
duties and the like shall be paid by [c.i.].

     4.3  Invoices for Products sold to DUSA shall be rendered and payable in
U.S. dollars. Products delivered to DUSA on consignment shall be paid for upon
resale by DUSA.

     5.   Relationship of the Parties.

     Both parties are independent contractors and not an agent or employee of
the other. Neither party is authorized to assume or create any obligation or
responsibility, including but not limited to obligations based on warranties or
guarantees or other contractual obligations, on behalf or in the name of the
other party. Neither party shall misrepresent its status or authority.

     6.   Regulatory Compliance.

     6.1  DUSA shall be responsible, at its own expense, to prepare, submit and
prosecute applications for all registrations and/or other regulatory approvals
required in connection with the sale and/or use of Products in the Territory.
Applications for approvals and registrations shall be in the name of DUSA.

     6.2  SOCHINAZ shall provide DUSA with all information in SOCHINAZ
possession useful or necessary for any and all regulatory approvals relating to
the manufacture of Product. DUSA shall not use such information for purposes
other than obtaining regulatory approvals except to the extent SOCHINAZ is
unable to supply DUSA's requirements of Products. Products hereunder in which
case DUSA shall be entitled to use such information to make or have made its
requirements of Products under the provisions of Paragraph 7 hereof.

     6.3  Each party shall immediately notify the other of any regulatory or
other administrative actions which come to that party's attention and which
affect Product.

     6.4  Without limiting any language stated above, SOCHINAZ shall manufacture
the Products according to the good manufacturing practices and good laboratory
practices established by the United States Foods and Drug Administration ("FDA")
from time to time. In addition, SOCHINAZ shall permit DUSA the right to
reference SOCHINAZ's drug master file as provided to the FDA to enable DUSA to
sell Products in the Territory.

     7.   Force Majeure; Inability to Supply.

     (a)  Neither party shall be responsible to the other for any failure or
delay in performing any of its obligations under this Agreement or for other
nonperformance hereof if such delay or nonperformance is caused by strike,
stoppage of labor, lockout or

                                       4
<PAGE>   5

other labor trouble, fire, flood, accident, act of God or of the Government of
any country or of any State or local government, or of the public enemy of
either, or by cause unavoidable or beyond the control of any party hereto.

     (b)  However, in the event a failure or delay occurs under subparagraph
7(a) above, or if SOCHINAZ is unable to supply Product as ordered for [c.i.],
then SOCHINAZ will immediately, but on a temporary basis only, provide to DUSA
or a third party mutually agreeable to DUSA and SOCHINAZ (and under the control
and responsibility of SOCHINAZ) with all technical information needed to produce
Product from commercially available starting materials, including, but not
limited to a copy of SOCHINAZ's drug master file, and shall permit the use of
such information to produce Product until SOCHINAZ is able to demonstrate to
DUSA that it is capable of producing product in the quantities and in the
timeliness required by DUSA on ongoing basis.

     8.   Warranties and Covenants.

     8.1  SOCHINAZ warrants that Product meets and will meet the specifications
set forth in Exhibit A, that the Product is and will be free from defects in
quality, material and workmanship and is and will be merchantable and fit for
its intended purpose. These warranties and covenants shall survive the
termination of this Agreement.

     8.2  SOCHINAZ warrants that it has title to and is the owner of all
information supplied hereunder related to the production of Product; that it
does not infringe any third parties' patents or trade secrets; and that it is
free to conduct the business contemplated by the parties hereto.

     8.3  SOCHINAZ warrants that Products and their production shall comply with
all applicable laws in the Territory including but not limited to the United
States Food, Drug and Cosmetic Act, as amended and will be manufactured in
accordance with good manufacturing practices, as defined therein.

     8.4  SOCHINAZ shall indemnify and hold DUSA harmless from and against any
and all expenses (including attorneys' fees), damages, claims, liabilities or
obligations whatsoever resulting from a defect in the Product or failure to meet
its specifications (a) any claim for personal injury or property damage arising
out of or resulting from the manufacture, supply contamination, adulteration, or
shipment of the Products delivered to DUSA, or (b) any claim for personal injury
or property damage arising out of or resulting from the representations or
warranties or breach thereof by SOCHINAZ as to the Product, or (c) any other act
or inaction of SOCHINAZ.

     9.   Term and Termination.

                                       5
<PAGE>   6

     9.1  This Agreement shall remain in effect for a period of five (5) years
from the date first the Product is first approved for any therapeutic use by the
United States Food and Drug Administration, unless sooner terminated in
accordance with Section 4.2 above or 9.2 or 9.3 below.

     9.2. SOCHINAZ may terminate this Agreement without further notice if any
one or more of the following events shall occur and shall not have been cured by
DUSA ninety (90) days after notice thereof from SOCHINAZ:

          (a)  DUSA shall fail to make any payment when due hereunder, or

          (b)  DUSA shall default in the performance or observance of any other
covenant, condition or agreement contained herein.

     9.3  DUSA may terminate this Agreement without further notice if any one or
more of the following events shall occur and shall not have been cured by
SOCHINAZ within ninety (90) days after notice thereof from DUSA:

          (a)  SOCHINAZ shall fail to provide to DUSA under this Agreement
Products which meet the specifications for such Products or shall fail to ship
such Products as required by this Agreement, or

          (b)  SOCHINAZ shall default in the performance or observance of any
other covenant, condition or agreement contained herein.

     10.  Confidentiality.

     10.1 The recipient of any proprietary information which is marked as such
if written, or which is confirmed in writing to be proprietary within thirty
(30) days after disclosure, if oral, shall at all times during the continuance
of this Agreement and for a period of seven (7) years after its termination:

          -    use such proprietary information exclusively for the purpose of
               and in accordance with the terms of this Agreement; and

          -    maintain such proprietary information confidential

and the recipient will accordingly not disclose any of such proprietary
information in whole or in part save for the purposes of and in accordance with
this Agreement.

     10.2 The foregoing restrictions on the recipient shall not apply:

                                       6
<PAGE>   7

          -    to any proprietary information which the recipient can show was
               already in its possession and at its free disposal before the
               disclosure by the other party.

          -    to any proprietary information which is hereafter disclosed to
               the recipient without any obligation of confidence by a third
               party who has not derived it directly or indirectly from DUSA or,
               as applicable, SOCHINAZ.

          -    to any proprietary information which is or becomes generally
               available to the public in printed publications in general
               circulation through no act or default on the part of the
               recipient or of the recipients' agents or employees.

     11.  Miscellaneous.

     11.1 This Agreement may not be assigned by either party, without the prior
written consent of the other party, except to the acquirer of substantially all
of the securities or assets of a party hereto, in conjunction with such
acquisition.

     11.2 This Agreement, including the exhibits attached hereto, constitutes
the entire agreement, superseding all prior oral or written agreements,
understandings, negotiations, conditions and warranties, between the parties
hereto on the subject hereof; and there are no conditions to this Agreement
which are not expressed herein.

     11.3 This Agreement may be modified or amended only by a writing signed by
both of the parties hereto.

     11.4 Notification required or permitted hereby shall be deemed given only
upon enclosure thereof in an envelope, sent by courier whose contract requires
that delivery be made within three (3) business days and which provides to the
sender a written acknowledgment of receipt by the addressee, and addressed to
the party to be given notification at the address to which that party has
previously notified the party giving notice that notices are to be sent or,
otherwise, to the address listed in conjunction with that party's name first set
forth above.

     11.5 This Agreement shall be governed by and construed in accordance with
the law of the State of New Jersey, United States of America. The court of
jurisdiction for all controversies shall be the U.S. District Court for New
Jersey.

     11.6 If any one or more provisions of this agreement shall be held to be
invalid, illegal or unenforceable, the validity, legality, or enforceability of
the remaining provisions shall not

                                       7
<PAGE>   8

in any way be affected or impaired thereby. In the event any provision shall be
held invalid, illegal or unenforceable, the parties shall use best efforts to
substitute a valid, legal and enforceable provision, which insofar as possible
implements the purposes thereof.

     IN WITNESS WHEREOF, the parties have caused their authorized officers to
execute this Agreement on the date first above written.

                                       SOCHINAZ S.A.

                                       By:  /s/ Christian Borgeaud
                                          --------------------------------------

                                       Title:  CEO
                                             -----------------------------------

                                       DUSA PHARMACEUTICALS, INC.

                                       By: /s/D. Geoffrey Shulman
                                          --------------------------------------

                                       Title:  President and CEO
                                             -----------------------------------

                                       8
<PAGE>   9

                                    EXHIBIT A

                                     to the

     DUSA Pharmaceuticals, Inc./Sochinaz S.A. Supply Agreement

     [c.i.]

<PAGE>   10

                                    EXHIBIT B

                                     to the

     DUSA Pharmaceuticals, Inc./Sochinaz S.A. Supply Agreement

     [c.i.]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00004-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00004-of-00352.parquet"}]]